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Lynn D. Wilson, MD, MPH,‡ Ramesh Rengan, MD, PhD,* and James M. Metz, MD*
Introduction: The potential benefits and long-term complications of
radiotherapy treatment for malignant thymoma are unclear. This is a
retrospective analysis of outcome in patients with malignant thy-
moma from the Surveillance, Epidemiology, and End Results data-
base between 1973 and 2005.
Methods: Of the 1987 patients identified, 1334 were analyzed.
Patients were categorized according to the Masaoka staging system
as stage I to IIA, IIB or III to IV. The primary end points were
overall survival, cardiac mortality, and the development of second-
ary malignancies.
Results: Patients received surgery and radiation (50%), surgery
alone (26%), radiation alone (12%), or no treatment (12%). The
median follow-up time for survivors was 65 months (range, 1–361
months). There was no significant increase in the 12-year cumulative
incidence rate of death from heart disease (10.2% radiation versus
7.5% no radiation, p 0.83) or incidence of secondary malignancies
(11.7% versus 12.4%, p  0.70) with radiation. Compared with
surgery alone, adjuvant radiation significantly improved overall
survival in patients with stage III to IV disease (p  0.04) and
demonstrated a nonsignificant trend in patients with stage IIB
disease (p  0.09). However, after excluding patients surviving less
than 4 months to account for surgical mortality, the benefit with
radiation was no longer significant (stage IIB: p  0.45, stage
III–IV: p  0.44).
Conclusions: Radiation does not seem to increase the risk of cardiac
mortality or secondary malignancy in patients with malignant thy-
moma. Although the routine use of postoperative radiotherapy in
malignant thymoma does not appear warranted, high-risk patients
may benefit from adjuvant radiation. This study can help to design
prospective trials to further establish the role of radiotherapy in
malignant thymoma.
Key Words: Thymoma, Radiation, Secondary malignancy, Cardiac
toxicity.
(J Thorac Oncol. 2010;5: 1454–1460)
Although thymic tumors are the most common tumors ofthe anterior mediastinum, they are relatively rare with a
reported incidence of 0.15 per 100,000 person-years.1 These
tumors are characterized as indolent with a lymphogenous
metastasis rate of 1.8% and an even rarer hematogenous
metastasis rate.2 Surgical resection is considered the mainstay
of treatment for malignant thymoma, and the extent of sur-
gical resection is an important prognostic factor.3 The role of
radiation therapy, however, is unclear.
The controversy regarding the use of radiation in ma-
lignant thymoma stems from the paucity of data on the topic.
Given the low incidence of malignant thymoma and the
excellent response to complete surgical resection, the use of
radiation therapy remains suboptimally defined. Prior studies
have suggested that Masaoka stage I tumors are adequately
controlled after complete surgical resection, whereas stage III
and IV thymomas have more of an apparent benefit from
adjuvant radiation therapy.3–6 Data regarding the use of
postoperative radiation in patients with stage II thymoma are
less clear.7
Given the proximity of the thymus to vital mediastinal
structures, there is a risk of radiation-induced cardiotoxicity
in patients who receive radiation therapy for malignant thy-
moma. The risk of cardiotoxicity has been well documented
in patients receiving thoracic irradiation for Hodgkin disease
and tangential fields for breast cancer. In addition to cardiac
morbidity, radiation therapy has been associated with the
development of secondary malignancies.8–14 The develop-
ment of leukemias, lymphomas, thyroid carcinomas, breast
carcinomas, and sarcomas is of particular concern in patients
with radiation exposure. Cardiac toxicity and the develop-
ment of secondary malignancies are considered long-term
complications of radiation therapy. Because patients with
malignant thymoma have favorable prognoses, the long-term
implications of treatment need to be evaluated.
This study was designed to examine the role of radia-
tion in the treatment of malignant thymoma in a large group
of patients from the Surveillance, Epidemiology, and End
Results (SEER) database. The clinical outcomes as well as
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the long-term morbidity and mortality from radiation treat-
ment are considered.
PATIENTS AND METHODS
This is a retrospective review of data from the National
Cancer Institute’s SEER program. Patients from 1973 to 2005
provided by 17 registries (San Francisco-Oakland, Connect-
icut, metropolitan Detroit, metropolitan Atlanta, Hawaii,
Iowa, New Mexico, Seattle, Utah, San Jose-Monterey, Los
Angeles, Alaska Natives, Rural Georgia, California exclud-
ing San Francisco/San Jose-Monterey/Los Angeles, Ken-
tucky, Louisiana, and New Jersey) were identified.
Malignant thymoma cases were identified by histology
(thymus  8580), primary site (thymus  379), and Interna-
tional Classification for Childhood Cancer site recode ex-
tended ICD-0-3 (XI [f.5] carcinomas of thymus). SEER only
collects data on “malignant” thymomas.1 Thymomas can be
classified as “malignant” or “benign” based on evidence for
capsular invasion. All cases reported to SEER after January 1,
2001, were coded for “ICD-0-3 histology and behavior” to
identify tumors by the World Health Organization (WHO)
histology classification system. Before January 1, 2001, how-
ever, thymic carcinoma cases (WHO histology type C) were
unable to be distinguished from malignant thymoma cases
and were therefore unable to be excluded from analysis. Data
on WHO histology were unavailable for more than 78% of
patients. Patients younger than 18 years, patients with miss-
ing surgery or radiation data, and patients with distinguish-
able thymic carcinoma histology were excluded from analy-
sis. Patients diagnosed in 2004 or 2005 were also excluded to
ensure an adequate follow-up time. Information about patient
demographics and tumor factors that could be associated with
overall survival (OS) was collected (age at diagnosis, sex,
race, marital status, SEER registry, and year of diagnosis).
The SEER database does not report chemotherapy use or
margin status.
Patients were staged according to the Masaoka staging
system for malignant thymoma. Patients were categorized
into three groups: I to IIA (“Invasive carcinoma confined to
gland of origin” or “Localized, NOS”), IIB (“Adjacent con-
nective tissue”), or III to IV (“Adjacent organs/structures in
mediastinum,” “further contiguous extension,” or “metasta-
sis”). Because the SEER database does not code for micro-
scopic capsular invasion, stage IIA patients were unable to be
distinguished from stage I patients. The category, “Adjacent
organs/structure in the mediastinum” probably included pa-
tients with pericardial or pleural dissemination. Therefore,
stage III patients were unable to be distinguished from stage
IV patients.
Patients were also divided into four groups according to
treatment: (1) surgery and radiation, (2) surgery alone, (3)
radiation alone, and (4) no treatment. Patients treated with all
types of surgery were included in the analysis. However,
patients coded as “Incisional, needle, or aspiration biopsy,”
“exploratory only,” or “surgery of regional and/or distant
sites/nodes only” were not considered to have undergone a
surgical resection. Radiation treatment consisted of “Beam
Radiation” or “Radiation, NOS.” The majority of patients
received radiation treatment after surgery; however, 36 pa-
tients received preoperative radiation and 6 patients received
radiation before and after surgery. The primary end points
were OS, cardiac mortality (cause of death, “COD to site
recode”  “Disease of the Heart”), and the development of
secondary malignancies. An additional OS analysis excluding
patients surviving less than 4 months was performed to
account for possible bias that would favor the adjuvant
radiation group.15,16
Statistical Analysis
Associations between the type of treatment and clinical
factors, demographic factors, and secondary malignancy de-
velopment were assessed using the 2 test, analysis of vari-
ance, and the Kruskal-Wallis test. Survival time was calcu-
lated as the number of months from the malignant thymoma
diagnosis date to the SEER date of death. Survival was censored
as of the last month when patients were known to be alive. OS
was investigated using survival curves generated by the Kaplan-
Meier approach and log-rank tests. Cox proportional hazards
models were used to analyze the association of treatment type
and covariates. Cardiac mortality was determined using the 2
test and cumulative incidence rate of death.
All statistical analyses were carried out using SAS version
9.1 (SAS Institute, Cary, NC), STATA/IC (Version 10.0 for
Windows, College Station, TX), or R version 1.1.1 (The R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline Patient Characteristics
From 1973 to 2005, a total of 1986 patients with
malignant thymoma were identified. There were 167 patients
with thymic carcinoma histology, 14 patients younger than 18
years, 212 patients with missing surgery or radiation data, and
331 patients diagnosed in 2004 or 2005. Seventy-two patients
met multiple exclusion criteria. After applying the exclusion
criteria, a total of 1334 patients were available for analysis.
The median follow-up time was 52 months (range, 0–361
months) for all patients and 65 months (range, 1–361 months)
for survivors.
The median age of the patient population was 58 years
(range, 18–94 years), 53% were male, 69% were Caucasian,
and 65.2% were married. Among the four treatment groups,
there was a significant difference in age, stage, and year of
diagnosis (p 0.001, Table 1) but no significant difference in
sex (p  0.70), race (p  0.21), marital status (p  0.15), or
WHO histology (p  0.82).
Analysis of OS
Figure 1 and Table 2 demonstrate OS rates for patients
with malignant thymoma by treatment group and stage. At
each stage, patients had improved OS with surgery and
radiation or surgery alone compared with radiation alone or
no treatment (p  0.001). Compared with surgery alone,
adjuvant radiation did not improve OS in patients with stage
I to IIA disease (p  0.43) but did significantly improve OS
in patients with stage III to IV disease (p  0.04). There was
a nonsignificant trend toward improved OS in stage IIB
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FIGURE 1. Kaplan-Meier curves of overall survival for the four treatment groups by stage.
TABLE 1. Characteristics of Study Patients
Variable (N)
Surgery and
Radiation
(N  669, 50.2%)
Surgery Alone
(N  346, 25.9%)
Radiation Alone
(N  155, 11.6%)
No Treatment
(N  164, 12.3%) p
Median age, yrs (SD) 55 (14.1) 60 (16.5) 64 (16.4) 64.5 (16.7) 0.001
Stage
I–IIA (278) 138 (49.6%) 114 (41.0%) 12 (4.3%) 14 (5.0%)
IIB (245) 166 (67.8%) 62 (25.3%) 8 (3.3%) 9 (3.7%)
III–IV (682) 342 (50.2%) 129 (18.9%) 107 (15.7%) 104 (15.3%) 0.001
Year of diagnosis
1973–1983 (158) 102 (64.6%) 49 (31.0%) 0 (0%) 7 (4.4%)
1984–1993 (320) 155 (48.4%) 82 (25.6%) 44 (13.8%) 39 (12.2%)
1994–2003 (856) 412 (48.1%) 215 (25.1%) 111 (13.0%) 118 (13.8%) 0.001
TABLE 2. Median Overall Survival by Stage, in Months (95% CI)
Surgery and Radiation Surgery Alone Radiation Alone No Treatment
All patients 117 (104–133) 130 (105–162) 34 (26–48) 35 (24–48)
Stage I–IIA 163 (138–214) 214 (153–267) 50 (10–108) 71 (p  0.76)a
Stage IIB 134 (110–162) 115 (77–170) 77 (6–108) 51 (p  0.95)a
Stage III–IV 97 (82–107) 76 (43–105) 34 (23–53) 35 (24–46)
a p value computed from log-rank test comparing no treatment vs. radiation alone.
CI, confidence interval.
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patients treated with adjuvant radiation (p  0.09). Radiation
alone did not improve OS at any stage when compared with
no treatment.
To control for surgical deaths and patients with signif-
icant morbidity, we excluded 75 patients surviving less than
4 months and performed the analysis for OS. The 4-month
mortality among patients treated with surgery alone was 3.5%
(4 of 114), 9.7% (6 of 62), and 11.6% (15 of 129) for stage
I to IIA, IIB, and III to IV, respectively. The mortality among
patients treated with surgery and radiation was 1.4% (2 of
138), 0.6% (1 of 166), and 2.0% (7 of 342) for stage I to IIA,
IIB, and III to IV, respectively. A total of 40 patients treated
with radiation alone or no treatment survived less than 4
months. After excluding patients surviving less that 4 months,
the difference between patients treated with surgery alone and
surgery and radiation, assessed by the log-rank test, was not
statistically significant (p  0.24), even among stage I to IIA
(p  0.22), IIB (p  0.45), or III to IV (p  0.44) patients.
A multivariable analysis of patients treated with sur-
gery and radiation or surgery alone was performed to deter-
mine associations between various patient factors and OS. In
the multivariable analysis, race, sex, and adjuvant radiation
were not associated with OS, whereas increasing age (hazard
ratio [HR] 1.03 [95% confidence interval [CI]: 1.02–1.04])
and increasing stage (stage I–IIA: HR  1, stage IIB: HR 
1.45 [95% CI: 1.09–1.93], stage III–IV: HR  2.3 [95% CI:
1.79–2.95]) were negative prognostic factors. Compared with
married patients, patients who were not married (HR  1.25
[95% CI: 1.02–1.53]) had poorer OS. Increasing year of
diagnosis was associated with improved OS. Patients diag-
nosed between 1984–1993 (HR  0.62 [95% CI: 0.48–
0.80]) and 1994–2003 (HR 0.50 [95% CI: 0.39–0.65]) had
improved OS compared with patients diagnosed between
1973 and 1983 (HR  1).
Cause of Death Analysis
A cause-specific mortality analysis was performed
on the 706 patients (52.9%) who died by the time of data
collection. The analysis demonstrated that 36.7% of pa-
tients died of malignant thymoma, 13.7% died of diseases
of the heart, and 49.6% died of all other causes. Patients
receiving radiation treatment did not have an increased rate
of cardiac mortality compared with patients not receiving
radiation (14.3% radiation versus 12.9% no radiation, p 
0.68). A separate analysis evaluating only patients with
stage I to IIA thymoma was performed. Patients with stage
I to IIA thymoma have longer survival compared with
patients with advanced disease and seem to have a worse
prognosis with adjuvant radiation (Figure 1 and Table 2).
The analysis with early-stage patients did not reveal a
significant increase in cardiac mortality with radiation
treatment (15.2% radiation versus 14.5% no radiation, p 
0.92). In addition, a separate analysis excluding patients
surviving less than 4 months was performed because cardiac
complications often account for postoperative deaths. In this
analysis, there was no increased rate of cardiac mortality in
the patients treated receiving radiation (14.4% radiation ver-
sus 12.0% no radiation, p  0.40).
The cumulative incidence rate of cardiac mortality for
patients receiving radiation versus those not receiving radia-
tion was 3.4% versus 5.9% at 6 years and 17.4% versus
11.8% at 24 years (Table 3 and Figure 2). The difference was
not statistically significant (p  0.83). Interestingly, there
was a nonsignificant decrease in the cumulative incidence
rate of death from all other causes of death in the radiation
group (p  0.06).
Secondary Malignancy Analysis
The incidence of secondary malignancy development
after treatment for malignant thymoma was analyzed. There
were a total of 159 patients (11.9%) who developed any
secondary malignancy and 56 patients (4.2%) who developed
a thoracic secondary malignancy. Thoracic malignancies
were cancers limited to the thyroid, breast, esophagus, and
lung. Comparing patients who received radiation (N  824)
and those who did not (N  510), there was no difference in
the development of all secondary malignancies (11.7% versus
12.4%, p  0.70) or thoracic secondary malignancies (3.4%
versus 4.3%, p  0.31). Table 4 summarizes the breakdown
of thoracic secondary malignancies by site as well as the
incidence of leukemia and lymphoma.
FIGURE 2. Cumulative incidence rate (CIR) of death. The
graph depicts the CIR of death from heart disease in patients
treated with (dashed) and without (solid) radiation therapy.
The plot also compares the CIR of death from all other
causes of death in patients treated with (dot-dash) or with-
out (dot) radiation therapy.
TABLE 3. Cumulative Incidence Rate of Death
Treatment, Cause of
Death (N) 3 yr 6 yr 12 yr 24 yr
Gray Test
p Value
No radiation, heart (36) 0.048 0.059 0.075 0.118 0.83
Radiation, heart (61) 0.021 0.034 0.102 0.174
No radiation, other cause
of death (243)
0.293 0.379 0.541 0.745 0.06
Radiation, other cause of
death (366)
0.225 0.355 0.532 0.699
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DISCUSSION
To our knowledge, this is the largest study to address
the long-term implications of radiation therapy in patients
with malignant thymoma. Because of the indolent nature of
malignant thymoma, patients with the disease tend to have
relatively good prognoses. With patients living for years after
treatment, the adverse effects related to radiation therapy are
of concern.
Malignant thymoma is associated with an increased risk
of secondary malignancy development independent of radia-
tion (OR  3.8, p  0.04).17 One analysis of 136 patients
with malignant thymoma concluded that the increased inci-
dence of secondary malignancies was not attributable to
radiation-induced malignancies.18 The effect of radiation on
the risk of secondary malignancy development after the
treatment of malignant thymoma is not well documented in
large cohorts of patients. Patients receiving mediastinal irra-
diation for various malignancies such as Hodgkin disease and
breast cancers are at an increased risk for secondary malig-
nancy.8,10,11,13 Solid tumor malignancies are found 9 to 60
years after radiation treatment, whereas leukemia and lym-
phomas are found between 5 and more than 15 years after
treatment.9,12,14 In our study, we did not demonstrate an in-
creased risk of secondary malignancy after radiotherapy. The
rates of all secondary malignancies and thoracic secondary
malignancies were similar between patients receiving radiation
and patients receiving surgery alone or no treatment.
In addition to increasing the risk of secondary malig-
nancies, radiation therapy to the chest increases a patient’s
risk for cardiotoxicity. Radiation-induced cardiotoxicity
seems to manifest more than 5 years after radiation treat-
ment.19 In particular, coronary artery disease seems to occur
greater than 10 years after treatment, and valvular diseases
tend to occur greater than 20 years after treatment.20 Patients
receiving radiotherapy for Hodgkin disease have a relative
risk of fatal cardiac complications ranging from 2 to 6.13
Patients receiving radiation treatment for left-sided breast
cancers have a relative risk of cardiac complications of 1.5 to
2.0.8–11 Even with the long-term survival rates in patients
with malignant thymoma, our analysis did not demonstrate a
significant difference in cardiac mortality between patients
who received radiotherapy and those who did not. However,
the cumulative incidence rate of death in Figure 2 demon-
strates a gradual increase in cardiac deaths after 10 years
among patients receiving radiation therapy. Although this
difference is not large enough to demonstrate a statistically
significant difference in cardiac mortality, the delayed in-
crease is a concern, and studies with longer follow-up are
needed.
Younger age and extensive fields of radiation are risk
factors for both cardiotoxicity and secondary malignancy. In
general, patients with malignant thymoma are older than
patients with Hodgkin disease. Also, the radiation treatment
fields for malignant thymoma are generally smaller than
mantle fields and tangent fields used to treat Hodgkin disease
and breast cancers, respectively. Therefore, age and radiation
field may have influenced the development of long-term
morbidities in patients with malignant thymoma.
In addition, combined modality treatment with chemo-
therapy and radiotherapy may have a synergistic effect on
long-term adverse events. In breast cancer, systemic agents
such as anthracyclines and trastuzumab are associated with
cardiac toxicity.9,21 In a study of 19,046 patients with
Hodgkin disease, treatment with alkylating agents without
radiotherapy was associated with an increased lung cancer
risk (RR  4.5 [2.1–8.8]). The risk increased with both
increasing numbers of cycles of alkylating agents and in-
creasing radiation dose.22 Patients with malignant thymoma
do not regularly receive adjuvant chemotherapy. Therefore,
the infrequent use of chemotherapy may have also contrib-
uted to the similar rates of cardiac toxicity and secondary
malignancy development in our study. Unfortunately, be-
cause of the limitations of the SEER database, we were
unable to gather information regarding the use of chemother-
apy in our patient population.
Although the long-term effects of radiation therapy do
not adversely affect patients with malignant thymoma, there
does not seem to be a benefit of radiation therapy in most
patients. Our study demonstrates that patients with stage I to
IIA thymoma do not benefit from adjuvant radiation, which is
consistent with the literature.3–6 The role of radiation in stage
II disease has been controversial. In our analysis, there was
initially a nonsignificant trend toward improved OS in stage
IIB patients treated with surgery and radiation (p  0.09).
After accounting for surgical mortality, the difference in
survival was not significant. Two recent SEER database
analyses have demonstrated improved survival in patients
with stage II or stage II to III thymoma.23,24 The differences
in staging and exclusion criteria, as described in Table 5, may
explain the discrepancies in survival among the various
analyses.
Interestingly, our results do not demonstrate a statisti-
cally significant benefit in OS with adjuvant radiotherapy in
patients with stage III to IV disease. Although a statistically
significant benefit was seen in an initial analysis, after ac-
counting for surgical mortality, the data were no longer
significant. Some studies have reported worse outcomes with
adjuvant radiation therapy;25 however, the majority of studies
support the role of radiation therapy in advanced-stage pa-
tients.4–6,26 From our secondary malignancy and cardiac
TABLE 4. Secondary Malignancies Among Patients with
Thymoma After Treatment with or without Radiation
(N  1334)
Radiation
(n  824)
No Radiation
(n  510)
Thyroid 1 (0.12%) 4 (0.78%)
Breast 12 (1.46%) 7 (1.37%)
Esophagus 3 (0.36%) 2 (0.39%)
Lung and bronchus 12 (1.46%) 9 (1.76%)
Lymphoma 10 (1.21%) 1 (0.20%)
Leukemia 7 (0.85%) 2 (0.39%)
All other malignancies 51 (6.19%) 38 (7.45%)
All sites 96 (11.65%) 63 (12.35%)
Overall p value  0.22
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mortality analyses, the difference in survival between the
analyses is probably not the result of long-term radiation-
induced toxicity. Instead, the unexpected survival rates may
be explained by the heterogeneity of the patients in the stage
III to IV group. Patients with stage IV disease likely receive
only palliative radiation. In addition, patients with high-risk
features such as positive margins and residual disease are more
likely to have inherently poor prognoses but are also more likely
to receive adjuvant radiation. Moreover, these are the patients
who benefit from radiation therapy. Finally, the high 4-month
mortality rate of 11.6% in stage III to IV patients treated with
surgery alone potentially affected our results.
On multivariable analysis of patients treated with sur-
gery and radiation or surgery alone, increasing age, increas-
ing stage, and earlier year of diagnosis were poor prognostic
factors. The improved survival observed in patients treated
during later years may be due to advances in surgical and
radiation techniques and technology as well as improved
patient selection.
At each disease stage, patients had improved OS with
surgery and radiation or surgery alone compared with radia-
tion alone or no treatment. Radiation alone did not improve
OS at any stage when compared with no treatment. The few
studies reporting data on patients treated with radiation alone
demonstrate modest disease control in patients with unresect-
able disease.27–29 When feasible, surgery is the primary treat-
ment for malignant thymoma.
Our results present important information regarding the
role of radiation therapy in malignant thymoma. As men-
tioned previously, this study is restricted by the inherent
limitations of the SEER registries. In addition to data regard-
ing chemotherapy, prognostic factors such as margin status
and performance status and information about radiation treat-
ment (dose, technique, completion rates, and type of technol-
ogy) were not available in the SEER database. WHO histol-
ogy classification was unavailable for the majority of patients
and was unable to be applied to this analysis. Also, patients
were unable to be classified further into distinct Masaoka
staging groups. Finally, although there does not seem to be a
significant risk of secondary malignancy development or
cardiac mortality with radiation treatment for malignant thy-
moma in this study population, longer follow-up is needed.
CONCLUSIONS
Because these data do not demonstrate a clear OS
benefit in patients treated with adjuvant radiation, this form of
treatment may not be appropriate for uniform use in all
patients. Radiation treatment should instead be considered for
patients on an individual basis with consideration of high-risk
features. Importantly, in our study, radiation therapy did not
increase the risk of death from heart disease or the incidence
of secondary malignancies. However, studies with longer
follow-up, adjuvant chemotherapy, WHO histology classifi-
cation, performance status, and margin status are needed to
further elucidate the role of radiation treatment in malignant
thymoma.TA
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